First-Line Market For Melanoma Not A Lock For Bristol Or Roche
This article was originally published in The Pink Sheet Daily
Data on Bristol's recently approved Yervoy and Roche's recently submitted vemurafenib show remarkable advances for melanoma but also establish competing options for first-line therapy.
You may also be interested in...
GSK presented Phase III results for its BRAF inhibitor dabrafenib and its MEK inhibitor trametinib at the American Society of Clinical Oncology annual meeting June 4. But the real excitement is over the just-starting Phase III trial combining the two drugs.
The drug makers, potential competitors, will study Bristol's CTLA-4 inhibitor Yervoy in combination with Roche's investigational BRAF inhibitor vemurafenib in metastatic melanoma.
Roche/Genentech seeks priority review and broad indication in metastatic melanoma for ground-breaking BRAF inhibitor.